Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Nicola Gökbuget(Goethe University Frankfurt), H Kantarjian(The University of Texas MD Anderson Cancer Center), Anthony S. Stein(University of Hohenheim), Tapan Maniar(Amgen (United States)), Mireia Morgades(Josep Carreras Leukaemia Research Institute), Norbert Ifrah(Institut National du Cancer), Sebastian Giebel(The Maria Sklodowska-Curie National Research Institute of Oncology), Michael Doubek(Central European Institute of Technology), Martha Wadleigh(Dana-Farber Cancer Institute), Véronique Haddad(Centre Léon Bérard), Aaron J. Katz(Amgen (United States)), D. Hoelzer(Oak Ridge National Laboratory), Hervé Dombret(University of London Institute in Paris), Jacob M. Rowe(Technion – Israel Institute of Technology), Michael A. Kelsh(Amgen (United States)), Giovanni Martinelli(University of Bologna), Christopher P. Holland(Amgen (United States)), Adele K. Fielding(New York Blood Center), Anjali S. Advani(Cleveland Clinic), Max S. Topp(Universitätsklinikum Würzburg), JM Ribera(Institut Català d'Oncologia), Victoria Chia(Amgen (United States)), Stephen O’Brien(The University of Texas MD Anderson Cancer Center), Renato Bassan(Pittini Group (Italy))
Cited by 128
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k